<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181973</url>
  </required_header>
  <id_info>
    <org_study_id>A6291026</org_study_id>
    <nct_id>NCT01181973</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Phase 1, Single-Dose Crossover Study to Evaluate Safety, Tolerability and Relative Bioavailability of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to
      that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg
      vial is safe and well-tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the pegvisomant concentration-time curve from time 0 to infinity hours post dose (AUCinf)</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the pegvisomant concentration-time curve from time 0 to last observed timepoint (AUClast)</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal pegvisomant concentration (Cmax)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The timepoint at which Cmax is obtained (Tmax)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life of pegvisomant (as data permit)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers IGF-1 (A few samples will be taken at timepoints around Tmax to observe the pegvisomant effect on IGF-1)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests (including hematology and serum chemistry parameters) and adverse events (including local site reactions)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Treatment sequence #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).</description>
    <arm_group_label>Treatment sequence #1</arm_group_label>
    <other_name>B2036-PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).</description>
    <arm_group_label>Treatment sequence #1</arm_group_label>
    <other_name>B2036-PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).</description>
    <arm_group_label>Treatment sequence #2</arm_group_label>
    <other_name>B2036-PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).</description>
    <arm_group_label>Treatment sequence #2</arm_group_label>
    <other_name>B2036-PEG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females between the ages of 21 and 55 years

        Exclusion Criteria:

          -  Positive urine drug screen

          -  Excessive use of alcohol or nicotine-containing products

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6291026&amp;StudyName=Safety%2C%20Tolerability%20and%20Relative%20Bioavailability%20of%20Pegvisomant%20in%20Healthy%20Subjects%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative bioavailability</keyword>
  <keyword>pegvisomant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

